Seres Therapeutics (MCRB) Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MCRB shares.
View MCRB analyst ratings or view top-rated stocks.

6 equities research analysts have issued 12-month price objectives for Seres Therapeutics' shares. Their MCRB share price forecasts range from $7.00 to $25.00. On average, they expect the company's stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 196.0% from the stock's current price.
View analysts price targets for MCRB or view top-rated stocks among Wall Street analysts.

Seres Therapeutics' stock was trading at $5.60 on January 1st, 2023. Since then, MCRB shares have decreased by 15.5% and is now trading at $4.73.
View the best growth stocks for 2023 here.

Seres Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 15,010,000 shares, an increase of 23.2% from the April 30th total of 12,180,000 shares. Based on an average daily trading volume, of 2,770,000 shares, the days-to-cover ratio is currently 5.4 days.
View Seres Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our MCRB earnings forecast.

Seres Therapeutics, Inc. (NASDAQ:MCRB) released its quarterly earnings data on Tuesday, March, 7th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.41) by $0.13. The biotechnology company earned $0.98 million during the quarter, compared to analysts' expectations of $9.04 million. Seres Therapeutics had a negative net margin of 3,509.50% and a negative trailing twelve-month return on equity of 1,977.08%.

ETFs with the largest weight of Seres Therapeutics (NASDAQ:MCRB) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Principal Healthcare Innovators ETF (BTEC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB) and ProShares Ultra Nasdaq Biotechnology (BIB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include OPKO Health (OPK), TherapeuticsMD (TXMD), Juno Therapeutics (JUNO), NVIDIA (NVDA), Walt Disney (DIS), Alibaba Group (BABA), Novavax (NVAX), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

(MCRB) raised $101 million in an initial public offering on Friday, June 26th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."

Seres Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FMR LLC (14.79%), Federated Hermes Inc. (11.95%), BlackRock Inc. (4.89%), State Street Corp (2.95%), Geode Capital Management LLC (1.28%) and Avoro Capital Advisors LLC (1.01%). Insiders that own company stock include David S Ege and Health Ltp Fund Ge Nutritional.
View institutional ownership trends.

Shares of MCRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MCRB stock can currently be purchased for approximately $4.73.

Seres Therapeutics (NASDAQ:MCRB) has a market capitalization of $604.97 million and generates $7.13 million in revenue each year. The biotechnology company earns $-250,160,000.00 in net income (profit) each year or ($2.30) on an earnings per share basis.

The company employs 333 workers across the globe.

Seres Therapeutics' mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The official website for the company is www.serestherapeutics.com. The biotechnology company can be reached via phone at (617) 945-9626 or via email at ctanzi@serestherapeutics.com.